Details der Publikation - Personalized marker-driven early switch to aflibercept in patients with metastatic colorectal cancer. A run in marker determination phase followed by a marker-driven randomized part - a multicenter, multinational, two-part, phase II trial.

Personalized marker-driven early switch to aflibercept in patients with metastatic colorectal cancer. A run in marker determination phase followed by a marker-driven randomized part - a multicenter, multinational, two-part, phase II trial. : Personalized marker-driven early switch to aflibercept in patients with metastatic colorectal cancer. A run in marker determination phase followed by a marker-driven randomized part - a multicenter, multinational, two-part, phase II trial.

Medienart:	Klinische Studie

Erscheinungsjahr:	2021
Erschienen:	2021

Enthalten in:	WHO International Clinical Trials Registry Platform - (2021) vom: 08. Nov. Zur Gesamtaufnahme - year:2021

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: colorectal cancer MedDRA version: 20.0Level: PTClassification code 10009944Term: Colon cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04] Phase: Phase 2 Recruitment Status: Authorised-recruitment may be ongoing or finished Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 30-06-2014, Last updated: 2022-11-24

ICTRP ID:	EUCTR2012-005657-24-DE PERMAD01

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	WHO004263987

Internformat


LEADER	01000caa a22002652 4500
001	WHO004263987
003	DE-627
005	20230425164838.0
007	cr uuu---uuuuu
008	210507s2021 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)WHO004263987
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2012-005657-24-DE
035			\|a (UBBS_Klinische_Studien_WHO)PERMAD01
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a Personalized marker-driven early switch to aflibercept in patients with metastatic colorectal cancer. A run in marker determination phase followed by a marker-driven randomized part - a multicenter, multinational, two-part, phase II trial. \|b Personalized marker-driven early switch to aflibercept in patients with metastatic colorectal cancer. A run in marker determination phase followed by a marker-driven randomized part - a multicenter, multinational, two-part, phase II trial.
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 30-06-2014, Last updated: 2022-11-24
650		4	\|a Medical Condition: colorectal cancer MedDRA version: 20.0Level: PTClassification code 10009944Term: Colon cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 2
650		4	\|a Recruitment Status: Authorised-recruitment may be ongoing or finished
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2021) vom: 08. Nov.
773	1	8	\|g year:2021 \|g day:08 \|g month:11
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005657-24 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
912			\|a SSG-OLC-PHA
951			\|a AR
952			\|j 2021 \|b 08 \|c 11

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände